Avanos Medical Inc

Avanos Medical, Inc. operates as a medical technology company. It focuses on delivering clinically medical device solutions to improve patients' quality of life. The firm’s portfolio of product offerings focuses on respiratory and digestive health, along with surgical and interventional pain management to improve patient outcomes and reduce the cost of care. Its brands include ON-Q, Coolife, Microcuff, MIC-Key, Quilbloc and Home pump. The company was founded on February 25, 2014 and is headquartered in Alpharetta, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Avanos Medical Inc reports robust Q4 results and outlines growth strategies

Avanos Medical Inc delivered strong financial performance in Q4 2022, showcasing growth in key product categories and exceeding expectations in OrthogenRx. While facing challenges in certain segments, Avanos is focused on optimizing operations and capitalizing on identified opportunities for growth.

Avanos Medical reports steady Q1 performance amidst strategic transformation

Avanos Medical Inc's Q1 2023 performance was steady, with a focus on operational efficiency and profitability enhancement.
While facing challenges in certain product categories, Avanos is well-positioned to capitalize on growth opportunities through strategic initiatives.
The company's transformation priorities and guidance for the year reflect a proactive approach to navigating market dynamics and driving sustainable value creation.

Avanos Medical Inc reports resilient Q2 performance and outlines growth strategies

Avanos Medical Inc demonstrated resilience in Q2 amidst supply chain challenges and inflation effects.
The company's focus on strategic priorities and shareholder value enhancement initiatives bode well for future growth.
Despite some portfolio challenges, Avanos remains optimistic about mid-single-digit revenue growth in 2024.
Operational efficiency and growth opportunities in key product lines position Avanos for sustained success.

Avanos Medical Inc reports Q3 results, focuses on efficiency and growth

Avanos Medical Inc's Q3 performance reflects mixed results with growth in Digestive Health but decline in Pain Management portfolios.
The company's transformation priorities and cost management efforts aim to drive efficiency and optimize performance.
Despite challenges in certain product segments, Avanos Medical Inc's focus on gross margin improvement and savings targets bode well for future profitability.
Opportunities lie in portfolio transformation, enhanced gross margins, and strategic initiatives like DIros Technology and cost optimization.

Avanos Medical Inc reports stable Q4 earnings amidst growth strategies

Avanos Medical Inc's Q4 performance reflects mixed results with challenges in certain product segments but stable profitability.
The company's strategic priorities aim to drive future growth through portfolio optimization and cost management.
Anticipated revenue growth, focus on M&A, and long-term financial targets position Avanos for sustainable performance and expansion.

Avanos Medical Inc reports solid Q1 performance and growth outlook

Avanos Medical Inc's Q1 2024 performance showed mixed results across portfolios but strong overall financials.
The company's focus on cost management, capital efficiency, and strategic targets bodes well for future growth.
Despite challenges in certain product lines, Avanos remains confident in its strategies and growth trajectory.

Avanos Medical reports resilient Q2 results amidst portfolio growth

Avanos Medical's Q2 performance showcased solid sales figures and growth in key portfolios, despite challenges in certain segments.
The company's strengths lie in maintaining financial guidance, a strong balance sheet, and a strategic focus on transformation initiatives.
While facing challenges in specific product lines, Avanos Medical has opportunities to drive growth through product innovation, strategic partnerships, and capital allocation.
Overall, Avanos Medical remains committed to its transformation journey and delivering value to shareholders through prudent financial management.

Avanos Medical reports Q3 results, focuses on growth strategies

Avanos Medical's Q3 performance reflects a mixed picture with strong Digestive Health growth but challenges in the pain portfolio.
The company's strategic focus on high-margin products, cost management, and growth initiatives positions it for future success.
Despite current challenges, Avanos Medical's pursuit of organic growth, efficient capital allocation, and strategic M&A bode well for long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Avanos Medical, Inc. is a medical technology company, which engages in delivering clinically superior medical device solutions and products to healthcare providers and patients. The company was founded on February 25, 2014 and is headquartered in Alpharetta, GA.

Investors continue to be optimistic about Avanos (AVNS), owing to its strong product line and focus on its R&D.

Here's Why You Should Hold on to Avanos (AVNS) Stock for Now

Charles River Laboratories

Ellington Financial

National Storage Affiliates Trust

S&P Global

Teledyne Technologies

NEW YORK, May 10, 2021 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600: S&P MidCap 400 constituent Charles River Laboratories International (NYSE:CRL) will replace FLIR Systems Inc. (NASD:FLIR) in the S&P 500, S&P SmallCap 600 constituent National Storage Affiliates Trust (NYSE:NSA) will replace Charles River Laboratories International in the S&P MidCap 400, and Ellington Financial Inc. (NYSE:EFC) will replace National Storage Affiliates Trust in the S&P SmallCap 600 effective prior to the opening of trading on Friday, May 14. S&P 500 constituent Teledyne Technologies Inc. (NYSE:TDY) is acquiring FLIR Systems in a deal to be completed soon pending final closing conditions.

Charles River Laboratories International Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

Avanos Medical (AVNS) continues to gain from its core Chronic Care segment in the first quarter.

Avanos Medical (AVNS) Q1 Earnings and Revenues Top Estimates

Avanos Medical, Inc.'s (AVNS) CEO Joe Woody on Q1 2021 Results - Earnings Call Transcript

ALPHARETTA, Ga., May 7, 2021 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported first quarter 2021 financial results.

Avanos Medical, Inc. Announces First Quarter 2021 Results

ALPHARETTA, Ga., April 30, 2021 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the first quarter 2021 on Friday, May 7 at 9 a.m.

Avanos Medical, Inc. To Webcast Conference Call Discussing First Quarter 2021 Financial Results

Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock?

Avanos Medical (AVNS) Down 1% Since Last Earnings Report: Can It Rebound?

ALPHARETTA, Ga., March 16, 2021 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Joe Woody, chief executive officer, will present at the Virtual KeyBanc Life Sciences & MedTech Investor Forum Tues.

Avanos Medical, Inc. to Present at the KeyBanc Life Sciences & MedTech Investor Forum

Investor confidence is high in Avanos Medical (AVNS) stock, courtesy of its solid prospects.

Here's Why You Should Retain Avanos Medical (AVNS) Stock Now

ALPHARETTA, Ga., Feb. 24, 2021 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Michael Greiner, senior vice president and chief financial officer, will present at the Virtual Raymond James 42nd Annual Institutional Investors Conference Mon., March 1 at approximately...

Avanos Medical, Inc. to Present at the Virtual Raymond James 42nd Annual Institutional Investors Conference

Avanos Medical (AVNS) continues to gain from its core Chronic Care segment in the fourth quarter.

Avanos Medical (AVNS) Q4 Earnings and Revenues Top Estimates

Avanos Medical, Inc. (AVNS) CEO Joe Woody on Q4 2020 Results - Earnings Call Transcript

Avanos Medical (AVNS) delivered earnings and revenue surprises of 27.27% and 0.67%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Avanos Medical (AVNS) Tops Q4 Earnings and Revenue Estimates

Shares of Avanos Medical (NYSE:AVNS) rose 0.1% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 17.65% year over year to $0.28, which beat the estimate of $0.22.

Recap: Avanos Medical Q4 Earnings

Investor confidence is high on Avanos Medical (AVNS), courtesy of solid prospects.

Why You Should Retain Avanos Medical (AVNS) Stock for Now

Why Is Avanos Medical (AVNS) Up 3.7% Since Last Earnings Report?

ALPHARETTA, Ga., Nov. 5, 2020 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that it would present at the following two virtual investor conferences in November: Conference: Stifel 2020 Virtual Healthcare Conference Presentation Date: Wed., Nov. 18 at approximately 10 a....

Avanos Medical, Inc. to Present at Two Virtual Investor Conferences in November

Avanos Medical (AVNS) continued to gain from core Chronic Care segment in the third quarter.

Avanos Medical (AVNS) Q3 Earnings and Revenues Top Estimates

Avanos Medical's (AVNS) CEO Joe Woody on Q3 2020 Results - Earnings Call Transcript

Avanos Medical (AVNS) delivered earnings and revenue surprises of 50.00% and 11.94%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Avanos Medical (AVNS) Q3 Earnings and Revenues Beat Estimates

ALPHARETTA, Ga., Nov. 3, 2020 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported third quarter 2020 financial results. "Thanks to the work of our team and their focus on execution, our momentum continued as we delivered results ahead of our expectations," stated Joe Woody,...

Avanos Medical, Inc. Announces Third Quarter 2020 Results

ALPHARETTA, Ga., Oct. 27, 2020 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the third quarter 2020 on Tuesday, Nov. 3 at 9 a.m. ET. The company will issue a news release detailing its results...

Avanos Medical, Inc. To Webcast Conference Call Discussing Third Quarter 2020 Financial Results

Investor confidence is high on Avanos Medical (AVNS), thanks to solid prospects.

Here's Why You Should Retain Avanos Medical Stock for Now

ALPHARETTA, Ga., Sept. 15, 2020 /PRNewswire/ -- Avanos Medical, Inc.

Avanos Medical, Inc. Appoints Michelle Scharfenberg as Senior Vice President & Chief Ethics and Compliance Officer

ALPHARETTA, Ga., Sept. 4, 2020 /PRNewswire/ -- Avanos Medical, Inc.

News for Avanos Medical Inc Stock (AVNS)